Primary central nervous system lymphoma: Is there still a role for radiotherapy?

Current Opinion in Neurology

Volumn 24, Issue 6, 2011, Pages 633-640

  Graber, Jerome J ^a   Omuro, Antonio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

methotrexate; neurotoxicity; primary central nervous system lymphoma; radiation leukoencephalopathy; radiation therapy

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; TENIPOSIDE; VINCRISTINE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MONOTHERAPY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA; METHOTREXATE; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TISSUE THERAPY; TREATMENT OUTCOME;

EID: 81855163376     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834cbdef     Document Type: Review

References (45)

1. CBTRUS: Statistical report: Primary brain tumors in the United States, 2004-2006. Central Brain Tumor Registry of the United States 2010; 32. Available at http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf
2. Nelson DF, Martz K, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: Can high dose large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): 8315. Int J Radiat Oncol Biol Phys 1992; 23:9-17.
3. Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group Protocol 88-06. J Clin Oncol 1996; 14:556-564. (Pubitemid 26051021)
4. Gabbai AA, Hochberg FH, Linggood RM, et al. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. J Neurosurg 1989; 70:190-194. (Pubitemid 19051713)
5. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992; 10:635-643.
6. DeAngelis LM, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20:4643-4648. (Pubitemid 36025280)
7. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18:3144-3150.
8. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group phase II trial 20962. J Clin Oncol 2003; 21:4483-4488. (Pubitemid 46594017)
9. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81:188-195. (Pubitemid 24237996)
10. O'Neill BP, Wang CH, O'Fallon JR, et al. The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment Group. Neuro Oncol 1999; 1:196-203.
11. Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005; 62:1595-1600. (Pubitemid 41434567)
12. Correa DD, Harder H, Klein M, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007; 18:1145-1151. (Pubitemid 47244358)
13. Gerstner ER, Zhu JJ, Engler DA, et al. High dose methotrexate for elderly patients with primary central nervous system lymphoma. Neuro Oncol 2008; 11:211-215.
14. Hoang-Xuan K, Chinot OL, Taillandier L. Treatment of primary central nervous system lymphoma in the elderly. Semin Oncol 2003; 30 (6 Suppl 19):53-57. (Pubitemid 38199166)
15. Omuro AM, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007; 85:207-211. (Pubitemid 47629402)
16. Ney DE, Reiner AS, Panageas KS, et al. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2010; 116:4605-4612.
17. Illerhaus G, Marks R, Muller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009; 20:319-325.
18. Bessell EM, Lopez-Guillermo A, Villa S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002; 20:231-236. (Pubitemid 34032616)
19. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25:4730-4735. (Pubitemid 350086474)
20. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374:1512-1520.
21. Ferreri AJM, Dell'Oro S, Foppoli M, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 2006; 66:1435-1438. (Pubitemid 43739659)
22. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, noninferiority trial. Lancet Oncol 2010; 11:1036-1047.
23. Batchelor T, Grossman SA, Carson K. Updated results of from NABTT CNS consortium studies in primary CNS lymphoma. Ann Oncol 2005; 16 (Suppl 5):v125.
24. Herrlinger U, Kuker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005; 57:843-847. (Pubitemid 40798622)
25. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21:4489-4495. (Pubitemid 46594018)
26. Pels H, Juergens A, Glasmacher A, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 2009; 91:299-305.
27. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as firstline treatment of primary CNS lymphoma. J Clin Oncol 2006; 24:3865-3870. (Pubitemid 46630733)
28. Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38:417-420. (Pubitemid 44340371)
29. Omuro A, Taillandier L, Chinot O, et al. Primary CNS lymphoma in younger patients: can whole-brain radiotherapy be deferred? J Neurooncol 2010; 104:323-330.
30. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-totreat analysis. J Clin Oncol 2003; 21:4151-4156. (Pubitemid 46606183)
31. Montemurro M, Kiefer T, Schuler F, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted wholebrain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007; 18:665-671. (Pubitemid 46523269)
32. Ferreri AJ, Verona C, Politi LS, et al. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys 2011; 80:169-175.
33. Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 2009; 91:315-321.
34. Morris PG, Abrey LE, Reiner AS et al. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leuk Lymphoma 2011; http://informahealthcare. com/doi/abs/10.3109/10428194.10422011.10585527[Epub ahead of print].
35. Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004; 90:353-358. (Pubitemid 38250628)
36. Joerger M, Huitema AD, Krahenbuhl S, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-677.
37. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003; 21:1044-1049. (Pubitemid 46594133)
38. Herrlinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002; 51:247-252. (Pubitemid 34111448)
39. Ferreri AJ, DeAngelis LM, Illerhaus G, et al. Whole-brain radiotherapy in primary CNS lymphoma. Lancet Oncol 2011; 12:118-119; author reply 119-120.
40. Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10:5643-5646. (Pubitemid 39180936)
41. Ekenel M, Iwamoto FM, Ben-Porat LS, et al. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 2008; 113:1025-1031.
42. Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010; 67:182-189.
43. Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008; 26:2512-2518.
44. Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19:742-749. (Pubitemid 32119089)
45. Graber JJ, Omuro A. Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate? CNS Drugs 2011; 25:447-457.